Clinical Trials
32 trialsNCT02629692 2026-05-13
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
Sun Pharma Advanced Research Company Limited
Phase 1/2 Terminated
NCT03320642 2025-10-21
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Incyte Corporation
Phase 1 Terminated
NCT00522990 2024-08-02
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
Astex Pharmaceuticals, Inc.
Phase 1/2 Terminated
NCT00346632 2024-05-17
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
Kyowa Kirin Co., Ltd.
Phase 1 Terminated
NCT02455024 2024-04-04
OMNI
Takeda
Terminated
NCT02228382 2021-12-30
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
Pfizer
Phase 4 Terminated
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT02078960 2021-11-09
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT01663766 2021-08-19
Phase I Study of Milatuzumab for Graft Versus Host Disease
Gilead Sciences
Phase 1 Terminated
NCT00644878 2021-08-18
MACS0254
Novartis
Phase 2 Terminated
NCT00449761 2021-07-15
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
Novartis
Phase 2 Terminated
NCT01300611 2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1 Terminated
NCT02115386 2019-12-10
MACS1532
Novartis
Phase 3 Terminated
NCT03547154 2019-08-12
C98026
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT01214655 2019-05-13
A Study for Patients With Acute Leukemia
Eli Lilly and Company
Phase 1 Terminated
NCT02204722 2018-06-15
IDEAL
Dong-A ST Co., Ltd.
Phase 4 Terminated
NCT02108951 2017-10-27
ENESTswift
Novartis
Phase 3 Terminated
NCT02200380 2017-04-07
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
Celldex Therapeutics
Phase 2 Terminated
NCT00664677 2016-02-23
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
Erimos Pharmaceuticals
Phase 1 Terminated
NCT00860535 2015-09-30
Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00464113 2015-08-21
Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia
Exelixis
Phase 1 Terminated
NCT00100152 2015-05-27
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00500006 2015-01-30
A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00114959 2015-01-15
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Terminated
NCT01650805 2014-11-17
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
Phase 3 Terminated
NCT01500161 2013-11-25
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Texas Oncology Cancer Center
Phase 2 Terminated
NCT00320190 2013-10-30
Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib
Bristol-Myers Squibb
Phase 2 Terminated
NCT00393380 2013-04-29
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
The Emmes Company, LLC
Phase 2 Terminated
NCT00058747 2012-09-07
AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevecâ„¢
Agenus Inc.
Phase 2 Terminated
NCT01066468 2012-03-13
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.
Novartis
Phase 1 Terminated
NCT00124748 2012-02-03
TOPS
Novartis
Phase 3 Terminated
NCT00519090 2011-11-07
ENEST
Novartis
Phase 3 Terminated